Skip to Content

Posts tagged with "Drug Development"

  • Drug Development

    Harvard to the Rescue

    Harvard is announcing a big initiative in systems biology, which is an interdisciplinary opportunity if there ever was one. The Initiative in Systems Pharmacology is a signature component of the HMS Program in Translational Science and Therapeutics. There are two broad goals: first, to increase significantly our knowledge of human disease mechanism… Read More
  • Cancer

    Too Many Cancer Drugs? Too Few? About Right?

    According to Bruce Booth (@LifeSciVC on Twitter), Ernst & Young have estimated the proportion of drugs in the clinic in the US that are targeting cancer. Anyone want to pause for a moment to make a mental estimate of their own? Well, I can tell you that I was a bit low. The E&Y number… Read More
  • Drug Assays

    Different Drug Companies Make Rather Different Compounds

    Now here’s a paper, packed to the edges with data, on what kinds of drug candidate compounds different companies produce. The authors assembled their list via the best method available to outsiders: they looked at what compounds are exemplified in patent filings What they find is that over the 2000-2010 period that not much change… Read More
  • Academia (vs. Industry)

    How Many New Drug Targets Aren’t Even Real?

    So, are half the interesting new results in the medical/biology/med-chem literature impossible to reproduce? I linked earlier this year to an informal estimate from venture capitalist Bruce Booth, who said that this was his (and others’) experience in the business. Now comes a new study from Bayer Pharmaceuticals that helps put some backing b… Read More
  • Drug Development

    GlaxoSmithKline Reviews the Troops

    Several readers sent along this article from the Times of London (via the Ottawa Citizen) on GlaxoSmithKline’s current research setup. You can tell that the company is trying to get press for this effort, because otherwise these are the sorts of internal arrangements that would never be in the newspapers. (The direct quotes from the… Read More
  • Business and Markets

    Chinese Pharma: No Shortage of Ambition, Anyway

    When does China take the next step in drug research? They already have a huge contract research industry, and they have branches of many of the major pharma companies. But when does a Chinese startup, doing its own research with its own people in China, develop its own international-level drug pipeline? (We’ll leave aside the… Read More
  • Alzheimer's Disease

    Bernard Munos Rides Again

    I’ve been meaning to link to Matthew Herper’s piece on Bernard Munos and his ideas on what’s wrong with the drug business. Readers will recall several long discussions here about Munos and his published thoughts (Parts one, two, three and four). A take-home message: So how can companies avoid tossing away billions on medicines tha… Read More
  • Drug Development

    2011 Drug Approvals Are Up: We Rule, Right?

    I’ve been meaning to comment on this article from the Wall Street Journal – the authors take a look at the drug approval numbers so far this year, and speculate that the industry is turning around. Well, put me in the “not so fast” category. And I have plenty of company there. Neither Bruce Booth… Read More
  • Chemical News

    Will Macrocycles Get It Done?

    Here’s an article from Xconomy on Ensemble Therapeutics, a company that spun off from work in David Liu’s lab at Harvard. Their focus these days is on a huge library of macrocyclic compounds (prepared by using DNA tags to bring the reactants together, which is a topic for a whole different post). They’re screening against… Read More
  • Drug Assays

    Phenotypic Screening For the Win

    Here’s another new article in Nature Reviews Drug Discovery that (for once) isn’t titled something like “The Productivity Crisis in Drug Research: Hire Us And We’ll Consult Your Problems Away”. This one is a look back at where drugs have come from. Looking over drug approvals (259 of them) between 1999 and 2008, the au… Read More